269 related articles for article (PubMed ID: 10816775)
1. [Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men].
Asscheman H; Gooren LJ
Ned Tijdschr Geneeskd; 2000 Apr; 144(18):847-50. PubMed ID: 10816775
[TBL] [Abstract][Full Text] [Related]
2. Testosterone supplementation: what and how to give.
Jockenhövel F
Aging Male; 2003 Sep; 6(3):200-6. PubMed ID: 14628500
[TBL] [Abstract][Full Text] [Related]
3. Testosterone treatment comes of age: new options for hypogonadal men.
Nieschlag E
Clin Endocrinol (Oxf); 2006 Sep; 65(3):275-81. PubMed ID: 16918944
[TBL] [Abstract][Full Text] [Related]
4. A ten-year safety study of the oral androgen testosterone undecanoate.
Gooren LJ
J Androl; 1994; 15(3):212-5. PubMed ID: 7928661
[TBL] [Abstract][Full Text] [Related]
5. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial.
Kühnert B; Byrne M; Simoni M; Köpcke W; Gerss J; Lemmnitz G; Nieschlag E
Eur J Endocrinol; 2005 Aug; 153(2):317-26. PubMed ID: 16061839
[TBL] [Abstract][Full Text] [Related]
6. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel.
Swerdloff RS; Wang C
Aging Male; 2003 Sep; 6(3):207-11. PubMed ID: 14628501
[TBL] [Abstract][Full Text] [Related]
7. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years.
Behre HM; von Eckardstein S; Kliesch S; Nieschlag E
Clin Endocrinol (Oxf); 1999 May; 50(5):629-35. PubMed ID: 10468929
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men.
Wang C; Ilani N; Arver S; McLachlan RI; Soulis T; Watkinson A
Clin Endocrinol (Oxf); 2011 Dec; 75(6):836-43. PubMed ID: 21689131
[TBL] [Abstract][Full Text] [Related]
9. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
[TBL] [Abstract][Full Text] [Related]
10. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy.
Lanfranco F; Zitzmann M; Simoni M; Nieschlag E
Clin Endocrinol (Oxf); 2004 Apr; 60(4):500-7. PubMed ID: 15049966
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
[TBL] [Abstract][Full Text] [Related]
12. The effects of pharmacologically induced hypogonadism on mood in healthy men.
Schmidt PJ; Berlin KL; Danaceau MA; Neeren A; Haq NA; Roca CA; Rubinow DR
Arch Gen Psychiatry; 2004 Oct; 61(10):997-1004. PubMed ID: 15466673
[TBL] [Abstract][Full Text] [Related]
13. Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction.
Mulhall JP; Valenzuela R; Aviv N; Parker M
Urology; 2004 Feb; 63(2):348-52; discussion 352-3. PubMed ID: 14972487
[TBL] [Abstract][Full Text] [Related]
14. [What is the interest of Klinefelter's syndrome for (child) psychiatrists?].
Kebers F; Janvier S; Colin A; Legros JJ; Ansseau M
Encephale; 2002; 28(3 Pt 1):260-5. PubMed ID: 12091788
[TBL] [Abstract][Full Text] [Related]
15. Transdermal testosterone therapy in the treatment of male hypogonadism.
Ahmed SR; Boucher AE; Manni A; Santen RJ; Bartholomew M; Demers LM
J Clin Endocrinol Metab; 1988 Mar; 66(3):546-51. PubMed ID: 3350906
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
17. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function.
Chiang HS; Hwang TI; Hsui YS; Lin YC; Chen HE; Chen GC; Liao CH
Int J Impot Res; 2007; 19(4):411-7. PubMed ID: 17538639
[TBL] [Abstract][Full Text] [Related]
18. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
von Eckardstein S; Nieschlag E
J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
[TBL] [Abstract][Full Text] [Related]
19. Treatment of hypogonadism in men with chronic kidney disease.
Johansen KL
Adv Chronic Kidney Dis; 2004 Oct; 11(4):348-56. PubMed ID: 15492971
[TBL] [Abstract][Full Text] [Related]
20. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism.
Merza Z; Blumsohn A; Mah PM; Meads DM; McKenna SP; Wylie K; Eastell R; Wu F; Ross RJ
Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
